The House Energy and Commerce Committee yesterday released a report on the 340B Drug Pricing Program. “The 340B program is an important program that enjoys strong bipartisan support in Congress,” the report says. “The program helps reduce the prices of covered drugs for certain participating entities who, in turn, provide care for patients.” The report, which comes after two years of the committee examining the operation and oversight of the 340B program, includes a number of findings about the program, as well as 12 recommendations.

Related News Articles

Headline
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…
Headline
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2017 data.
Headline
The House Energy and Commerce Health Subcommittee today held a hearing to discuss seven bills aimed at increasing competition in the prescription drug market…
Headline
The Senate Special Committee on Aging today concluded a two-part hearing on the impact of rising prescription drug costs on seniors and potential policy…
Headline
Eight in 10 U.S. adults say prescription drug costs are “unreasonable,” and one in four say their prescription medicines are difficult to afford, according to…
Perspective
Patients and their providers rely on these prescription drugs for treating injury and managing illness. Yet the drug companies and their shareholders have been…